Objetivo
Diabetes is a major health problem in Europe. Limited availability of donor tissue restricts conventional transplant treatments. Therefore, we propose to bioengineer pancreatic islet microorgans (called pseudoislets) using glucose-responsive insulin-producing cells of differentiated stem cell origin. These microorgans should be suitable substitutes to restore the function of the destroyed pancreatic islets in a diabetic individual. The combination of the bioengineering of insulin-secreting surrogate cells with techniques for generation of a pancreatic islet microorgan represents a highly innovative experimental approach. This Cell Factory concept for an innovative insulin replacement therapy, applied to cells of human origin, can offer, due to the unlimited supply, a cure to many diabetic patients. The long-standing expertise and experience of the partners in this proposal bring together the capabilities to achieve this highly desirable goal.
Ámbito científico
Convocatoria de propuestas
Data not availableRégimen de financiación
CSC - Cost-sharing contractsCoordinador
30625 HANNOVER
Alemania